The strain Bacillus licheniformis D-13 produces three hydrophobic peptides (amoebicins d13-A, d13-B, and d13-C) that elicit antiamoebic activity against human-pathogenic and nonpathogenic species of Naegleria and have a broad spectrum of antibacterial activity. The three amoebicins have the same amino acid composition (three Asp, two Glu, two Val, and nine Leu residues) and molecular weight (1,870). Amoebicin d13-B causes lysis of amoebae through disorganization of the cell membrane. It also induces permeability to 86Rb and membrane disruption in asolectin vesicles.
The strain Bacillus licheniformis D-13 produces three hydrophobic peptides (amoebicins d13-A, d13-B, and d13-C) that elicit antiamoebic activity against human-pathogenic and nonpathogenic species of Naegleria and have a broad spectrum of antibacterial activity. The three amoebicins have the same amino acid composition (three Asp, two Glu, two Val, and nine Leu residues) and molecular weight (1, 870) . Amoebicin d13-B causes lysis of amoebae through disorganization of the cell membrane. It also induces permeability to 86Rb and membrane disruption in asolectin vesicles.
Free-living amoebae of the genera Naegleria and Acanthamoeba are able to cause diseases in humans and other animals. Normally, these amoebae live as phagotrophs in moist environments, ponds, rivers, streams, and lakes, where they feed on bacteria (6, 15, 20, 26, 27) . However, as opportunists they may produce serious infections of the eye and central nervous system. The biology, ecology, and pathology of opportunistically pathogenic, free-living amoebae have been reviewed recently in detail (12) . Naegleria fowleri is responsible for a rapidly fatal infection involving the central nervous system called primary amebic meningoencephalitis (4, 13) . Infection often occurs in healthy young people who have a recent history of swimming in fresh water. The most widely used antibiotic against this disease is amphotericin B (19, 23) . Other compounds have been reported to have antiamoebic activity in vitro (8, 19, 22, 24, 25) , but their efficacy in vivo has not been proved. The reduced number of chemotherapeutic agents available for treatment of this disease and their limited efficacy and toxic side effects are the main concerns in the search of new antiamoebic substances.
A screening for the production of antiamoebic substances by bacteria isolated from soil, mud, and water samples was carried out in our laboratory. Three strains of Bacillus licheniformis isolated from soil (named A12, D-13, and M-4) showed a marked amoebolytic activity against human-pathogenic amoebae (5) . Activity from strain M-4 was best produced during sporulation in media buffered at pH 5.8. Partially purified preparations from this strain obtained by ammonium sulfate precipitation and gel filtration showed strong amoebolytic activity and a narrow antibacterial spectrum (5) . Moreover, two amoebolytic substances (amoebicins A12-A and A12-B) were purified from strain A12. They were hydrophobic peptides with a low molecular weight (1, 430) containing the amino acids Asp, Glu, Ser, Pro, and Tyr. Both peptides were active against pathogenic amoebae and fungi (9) . The purification and biological activity of new antiamoebic peptides produced by strain D-13 are reported in this paper.
MATERIALS AND METHODS
Microorganisms and culture conditions. The producer strain B. lichenifornis D-13 was isolated from a soil sample (5) . The amoebae used in this study (see Table 3 ) and their growth conditions are described elsewhere (9) . For the assays of biological activity, amoebae were grown axenically in Cline medium (14) . Peritoneal and splenic cells obtained from BALB/c mice as described previously (18) were grown in RPMI 1640 (Sigma) supplemented with 10% bovine fetal serum (RPMI-BFS) at 37°C under a 5% CO2 atmosphere.
Activity assays. Samples were assayed for antiamoebic activity as described elsewhere (9), in 6.4-mm-diameter flatbottomed microtiter wells (96-well microtiter plates; Corning Glass Works, Corning, N.Y.) containing 6 x i03 amoebae in a final volume of 200 ,lI. The cytological effects were visualized under an inverted light microscope (Carl Zeiss, Jena, Germany). The number of intact amoebae was determined with a hemocytometer.
Purified amoebicins were tested on murine cells by a colorimetric assay using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma] as described elsewhere (16) . Cells were incubated with amoebicins in 96-well microtiter plates at 4 x 103 cells per well. At desired intervals, 50 ,ug of MTT in phosphate-buffered saline was added to each well and the cells were incubated for 4 h before the results were read on a Whittaker microplate reader 2001 as described previously (16) .
The antibacterial activity of amoebicins was tested as described previously (9) . One arbitrary unit (AU) was defined as the highest dilution of the sample to cause lysis of ca. 50% of the amoebae or to produce a visible halo of inhibition on a bacterial lawn. The titer, in AU per milliliter, was calculated from the inverse of this dilution.
Production of amoebicidal activity. The production of amoebicins by B. licheniformis D-13 was tested in brain heart infusion (BHI) (BBL, Cockeysville, Md.) or tryptic soy broth (BBL) dissolved in 75 mM sodium phosphate buffer, pH 7.2, as described previously (5) , and the antiamoebic activity of cellfree supernatants was determined.
Purification of antiamoebic activity. One liter of culture supernatant of the producer strain was mixed with 500 ml of methanol and passed through a column ( 50 ml of methanol-acetonitrile (1:1, vol/vol). The eluate was lyophilized and redissolved in 50 ml of methanol-water (1:2, vol/vol). Portions (10 ml) of this material were loaded on a Spherisorb C-6 column (1 by 25 cm) (Phase Separations, Inc., Norwalk, Conn.) in 10 mM trifluoroacetic acid (TFA) and separated with two combined linear gradients (0 to 20% over 5 min and 20 to 100% over 30 min) of isopropyl alcoholacetonitrile (2:1) in 4 mM TFA at a flow rate of 2 ml/min. The eluate was collected in different fractions, which were lyophilized and redissolved in 30% methanol before they were tested for antiamoebic activity. The active fractions were loaded separately on an Ultrapore reversed phase solid chromatography column (0.4 by 7.5 cm) (Altex, Berkeley, Calif.) equilibrated in 10 mM TFA. The column was eluted with a 40 to 100% linear gradient of isopropyl alcohol-acetonitrile (2:1) in 4 mM TFA over 20 min at a flow rate of 1 ml/min.
The molecular weights of the amoebicins were estimated by gel filtration. Aliquots (20 ,ul) were chromatographed on a glass column (3 by 500 mm) (Omni International Inc., Waterbury, Conn.) packed with Fractogel TSK HW-50 (S) (Merck, Darmstadt, Germany) in 75% methanol. The column was operated with a Pharmacia-LKB high-pressure liquid chromatography (HPLC) system (Pharmacia, Barcelona, Spain) at a flow rate of 9 ml/h. Aprotinin (6.5 kDa), bacitracin (1.4 kDa), polymyxin B (1.2 kDa), valinomycin (1.1 kDa), and erythromycin (0.73 kDa) were used as markers.
Physicochemical characterization. Active samples were tested for sensitivity to extremes of heat and pH or to inactivation by the enzymes trypsin, pronase, proteinase K, ,B-glucuronidase, and lipase as described elsewhere (9) .
The sample protein concentration was determined by the method of Bradford (2), and the presence of phosphorus and neutral sugars was quantitated by methods described elsewhere (1, 7). The optical absorbance spectrum of the purified amoebicins was recorded in a UV/Vis Beckman DU-70 spectrophotometer. Amino acid composition was determined as described previously (10) , and the protein content was correlated with the recorded absorbance in order to calculate the extinction coefficients. The N-terminal amino acid sequence was determined by Edman degradation with an Applied BioSystems 470A protein sequencer. Fatty acid analysis was carried out by a previously described procedure (9, 21). 
RESULTS
Bacterial growth and amoebicin production. The highest yields of antiamoebic activity were obtained when the producer strain was grown in BHI broth buffered with 75 mM sodium phosphate, pH 7.2. Production of activity in this medium was not affected by incubation temperatures of 28 or 37°C, but it was favored (1.5-fold) by agitation.
Production of antiamoebic activity occurred during late stationary phase, regardless of the growth conditions tested. The relationship between amoebicin production and sporulation was investigated in cultures grown in buffered BHI broth at 28°C under agitation. Amoebicidal activity was detected in culture supernatants at the onset of sporulation, and its production reached a plateau of 65 AU/ml at 60 h (Fig. 1) . For practical reasons, the cultures were collected at 72 h of incubation and the cells were removed by centrifugation.
Purification. Antiamoebic activity from the spent medium of B. licheniformis D-13 was retained by solid-phase extraction LC-8 bulk packing at 33% methanol while the pigmented material from the broth was washed off. Activity in the partially purified concentrate was further separated from most of the contaminants by reversed-phase chromatography on a Spherisorb C-6 column. Three peaks of A210 (but none at 280 nm) were detected at the position where amoebicidal activity eluted (at a 60% concentration of solvent B). When the fractions corresponding to the three peaks were chromatographed separately on a Ultrapore reversed-phase column, they eluted at slightly different retention times (Fig. 2) . The highly purified listed in Table 1 . The amount of amoebicin dI3-B recovered was slightly larger than those of the other two. The percentage of activity found in the purified fractions was 23% of the initial activity.
Physicochemical characterization. The three amoebicins were stable in a pH range from 2.5 to 9.5, and they retained 100% of the activity after being heated at 100°C for 30 min and also after being stored at -20°C for 6 months. Since purified amoebicins were not soluble in aqueous buffers, a mixture of partially purified amoebicins in 20 mM Tris-HCl (pH 7.2) was tested for sensitivity to various enzymes. The mixture retained 100% of its activity after being treated for 1 h with proteases (trypsin, pronase, and proteinase K), lipase, or ,-glucuronidase.
The purified amoebicins did not contain any phosphorus, fatty acids, or neutral sugars. The three fractions had identical amino acid compositions: Asp, Glu, Val, and Leu ( Table 2) . The minimum molecular weight estimated from their amino acid contents was 1,870. The three amoebicins eluted at the same volume on a Fractogel TSK HW-50 (S) column, and this corresponded to a molecular weight of 1,700. Amoebicins showed a maximum light A210, but none above 240 nm. The E210 extinction coefficients calculated from the protein content and the UV absorbance (in [milligrams per milliliter]-' x centimeter-') were 6.69 x 10-3, 6 .82 x 10-3, and 6.58 x 10-3 for amoebicins d13-A, d13-B, and d13-C, respectively. No amino acid residues were detected after the N-terminal sequence of amoebicin d13-B, suggesting that this peptide is cyclic or blocked at its amino terminus.
Spectrum of inhibition and biological activity. Purified amoebicins were active against several bacteria, most of them gram-positive species (Table 3) . Both pathogenic and nonpathogenic species of Naegleria were susceptible, while Acanthamoeba sp. strain Gr-1 was resistant. The specific activity of amoebicin d13-B against N. fowleri HB-1 was 1.86 AU/,ug of protein in our assay (0.55 jig in 200 ,ul). Addition of purified amoebicins to exponentially growing trophozoites of N. fowleni HB-1 caused a progressive decrease in the number of cells that was proportional to the amount of amoebicin added. The effect of amoebicin d13-B on the number of cells is shown in Fig. 3 . Changes in the morphology of treated amoebae were easy to observe under an inverted light microscope. First, the cells became round with a dense granular cytoplasm, and substantial lysis of the cell population occurred soon after. Past 10 h of incubation, the cultures contained abundant cell debris, but no intact amoebae were found. Amoebae stained with DAPI were observed under a fluorescence microscope. Treatment with amoebicin d13-B caused lysis of the cell membrane and loss of the cytoplasmic content, while the nuclei remained intact and stained with the fluorescent dye. Some nuclei surrounded by membrane ghosts could also be observed.
Preparations of amoebae treated with amoebicin d13-B for different periods of time were observed under a scanning electron microscope (Fig. 4) . Amoebae turned into round cells after 10 min of treatment (Fig. 4A) . Visible damage to the cell membrane could be observed after 20 min of incubation (Fig.  4B) . After 40 min, the preparations contained severely damaged amoebae whose cytoplasmic content had burst out because of chaotic disorganization of the cell membrane (Fig.  4C) .
Liposomes loaded with 86Rb were treated with amoebicin d13-B (1 ,ug/ml) for various periods (Fig. 5) . A rapid efflux of 86Rb was observed following addition of this amoebicin.
Treated liposomes lost 90% of trapped 86Rb after 15 min of incubation. It was not necessary to generate an artificial membrane potential across the liposome membrane for amoebicin d13-B to be active on the membrane.
Liposomes treated with amoebicin d13-B were observed by transmission electron microscopy (Fig. 6) . A short treatment with amoebicin induced the formation of peculiar cloverleaflike structures (Fig. 6B ). Further treatment with amoebicin caused lysis of the liposomes (Fig. 6C) .
DISCUSSION
The production of antibiotics with antiamoebic activity by strains of B. licheniformis isolated from natural habitats may be important for various reasons. First, the severity of the disease caused by human-pathogenic amoebae is a stimulus for the trial of new antibiotics. Second, there may be ecological implications since producers of amoebicins may share the same habitats as amoebae. Finally, amoebicins may constitute a new class of antibiotics from Bacillus spp.
The three substances with antiamoebic activity purified from culture supernatants of B. licheniformis D-13 are hydrophobic peptides with identical molecular weights and amino acid compositions. The similarity in the chemical and physical characteristics of the three fractions isolated suggests that they may be the same substance. However, slight differences must exist to account for their different retention times on HPLC.
The production of various substances with antiamoebic activity by different strains of B. licheniformis has common features: (i) production occurs during sporulation; (ii) the substances produced by strains A12 and D-13 consist of two or three related peptides with low molecular weights; (iii) both types of amoebicins lack a free amino terminus, suggesting that they may be cyclic peptides; and (iv) the amoebicins are very resistant to extremes of pH, heat, and proteolytic enzymes. Although both types of amoebicins contain the amino acid residues Asp and Glu, the rest of the residues are different, as are the spectra of UV light absorbance. The amino acid compositions of amoebicins from B. licheniformis D-13 are also 1318 different from those of other antibiotics from B. licheniformis (3, 11, 17) . The antiamoebic spectrum of amoebicins from B. licheniformis D-13 is restricted to species of Naegleria, while Acanthamoeba sp. strain Gr-1 is resistant. This strain is also resistant to purified amoebicins from B. licheniformis A12 (9) and to crude extracts from B. lichenifornis M-4 (5). Amoebicins from strain D-13 are also active against several bacteria, the most susceptible strains belonging to the genera Bacillus, Corynebacterium, Enterococcus, and Mycobacterium. These strains are at least twice as susceptible as amoebae.
Preliminary cytotoxicity assays indicate that murine cells are affected by amoebicins. Nevertheless, they are much less sensitive than amoebae since the amount of amoebicin required to partially reduce the number of viable cells during a 12-h incubation period was fourfold higher than that required to reduce the number of intact amoebae by 50% in 1 h. It may be possible to chemically modify the structure of amoebicins in order to modulate their biological activity and selectively minimize undesirable side effects.
The type of damage caused by amoebicins on amoebae and liposomes clearly indicates that the primary site of action is the cell membrane. Furthermore, localized membrane damage can be observed on preparations of amoebicin-treated amoebae or liposomes examined under an electron microscope. It is tempting to suggest that amoebicins from strain D-13 are therefore cytolytic pore-forming peptides.
